Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | IDH1 | O75874 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259390 | 0.88 | MEN1 (0.66) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7571566 | 0.86 | SMN1; SMN2 (0.57) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7580547 | 0.86 | IDH1 (0.71) | L3MBTL1SMN1; SMN2IDH1 | |
| SCHEMBL95317 | 0.86 | SMN1; SMN2 (0.60) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7571585 | 0.86 | ALDH1A1 (0.66) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL15646419 | 0.85 | MEN1 (0.67) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL3470566 | 0.84 | SMN1; SMN2 (0.67) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL11407805 | 0.84 | CA2 (0.63) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7571531 | 0.84 | SMN1; SMN2 (0.67) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL23832738 | 0.83 | CA12 (0.61) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202339-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202339-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| CN-104822373-B | Therapeutic compound and composition | 安吉奥斯医药品有限公司 | 2018-08-28 | — | — | CN | disclosed |
| US-20150299115-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2906212-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-104822373-A | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS INC | 2015-08-05 | — | — | CN | disclosed |
| WO-2014062511-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202339-B2 | Therapeutic compounds and compositions | IDH3A, IDH1, IDH2 | L3MBTL1 1282/4885SMN1; SMN2 524/4885MAPT 4036/4885 |
| US-20150299115-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | IDH3A, IDH1, IDH2 | L3MBTL1 1282/4885SMN1; SMN2 524/4885MAPT 4036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.